Canterbury DHB


Congenital Platelet Function Defects

Platelet disorders can be treated with desmopressin, platelet transfusion, or recombinant factor VIIa.

Desmopressin shortens the bleeding time, at least partially, in the majority of patients with mild bleeding disorders secondary to platelet function abnormalities. The mechanism for this effect is unknown and may be due to vessel wall constriction. A therapeutic trial is indicated where possible to determine if an individual patient is desmopressin responsive.

In cases of more severe bleeding, a platelet transfusion may be required. There is some evidence that patients with congenital bleeding disorders respond to recombinant factor VIIa, however this should not be used without consultation with a haematologist.

About this Canterbury DHB document (5282):

Document Owner:

Mark Smith (see Who's Who)

Issue Date:

August 2016

Next Review:

August 2019


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5282